|
|
|
| home > white papers > Overcoming research challenges with Adaptive Trials - PCI Pharma Services |
|
|
 WHITE PAPERS |
|
PCI Pharma Services
|
|
Overcoming research challenges with Adaptive Trials
|
|
There has been cause for concern within the pharmaceutical industry over
the last five years, regarding increasing research and development
costs, combined with a fall in the number of new drugs brought to
market. In an attempt to overcome this issue there has been a
significant rise in the use of adaptive clinical trial designs, whilst
saving time and money as well as facilitating more effective decision
making. One of the biggest challenges that pharmaceutical companies have
experienced has been delivering compliant clinical trials supplies
across diverse patient populations in the relatively short timeframes
that adaptive trial designs require, remaining focused on ensuring that
patient compliance and product quality is in no way compromised. This
demand has led to the launch of fast response services that support
Research and Development in responding to changing dosing regimens
mid-trial.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics
IRBM, a global contract research organization (CRO), has strengthened
its position in neurodegenerative disease research following an
extension of its long-standing collaboration with CHDI Foundation, a
nonprofit biomedical research organization exclusively dedicated to
collaboratively developing therapeutics that substantially improve the
lives of those affected by Huntington’s disease (HD).
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
Synergy Research Group
In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >> |
|
 |
Industry Events |
 |
PDA Europe Annual Meeting 2019
24 June 2019, Hilton Amsterdam
Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >> |
|
|
|
